- Home
- GH vs SNRE Comparison
GH vs SNRE Comparison
Compare GH & SNRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- SNRE
- Stock Information
- Founded
- GH 2011
- SNRE 2000
- Country
- GH United States
- SNRE Switzerland
- Employees
- GH N/A
- SNRE N/A
- Industry
- GH Medical Specialities
- SNRE Cable & Other Pay Television Services
- Sector
- GH Health Care
- SNRE Telecommunications
- Exchange
- GH Nasdaq
- SNRE Nasdaq
- Market Cap
- GH 6.1B
- SNRE 4.1B
- IPO Year
- GH 2018
- SNRE N/A
- Fundamental
- Price
- GH $47.17
- SNRE $50.18
- Analyst Decision
- GH Strong Buy
- SNRE
- Analyst Count
- GH 15
- SNRE 0
- Target Price
- GH $42.57
- SNRE N/A
- AVG Volume (30 Days)
- GH 2.6M
- SNRE 443.6K
- Earning Date
- GH 02-20-2025
- SNRE 02-18-2025
- Dividend Yield
- GH N/A
- SNRE N/A
- EPS Growth
- GH N/A
- SNRE N/A
- EPS
- GH N/A
- SNRE N/A
- Revenue
- GH $692,256,000.00
- SNRE $3,604,493,743.00
- Revenue This Year
- GH $32.40
- SNRE N/A
- Revenue Next Year
- GH $16.92
- SNRE N/A
- P/E Ratio
- GH N/A
- SNRE N/A
- Revenue Growth
- GH 29.20
- SNRE N/A
- 52 Week Low
- GH $15.81
- SNRE $42.35
- 52 Week High
- GH $50.89
- SNRE $50.67
- Technical
- Relative Strength Index (RSI)
- GH 66.04
- SNRE N/A
- Support Level
- GH $44.10
- SNRE N/A
- Resistance Level
- GH $50.89
- SNRE N/A
- Average True Range (ATR)
- GH 2.75
- SNRE 0.00
- MACD
- GH 0.21
- SNRE 0.00
- Stochastic Oscillator
- GH 74.24
- SNRE 0.00
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About SNRE Sunrise Communications AG American Depositary Shares representing Class A shares
Sunrise Communications AG is a telecommunications company. The company provides high-quality mobile, landline, broadband, and TV services to residential customers. The company also offers business customers 360-degree communications solutions and integrated ICT solutions for connectivity, security, and IoT from a single source to take companies forward in their quest for digitalization.